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Chronic Cavitary Pulmonary Aspergillosis with Aspergilloma in a Previously
Healthy Teenager
Michael McDowell Jr, DO; 1 Wendy Estrellado-Cruz, MD 2
Department of Pediatrics, Children's Mercy Hospital and Clinics, Kansas City, MO 1; Department of
Pediatrics, Division of Pulmonary and Sleep Disorders Center, Children's Mercy Hospital and Clinics,
Kansas City, MO2
Introduction: Hemoptysis is a rare and dangerous complication of chronic pulmonary aspergillosis. This
is a unique case of a previously healthy teenager presenting with chronic cough, hemoptysis and
cavitary lung lesion.
Case Presentation: A previously healthy 16 year-old male was admitted with chronic cough and
hemoptysis. He was previously treated with antibiotic for right upper lobe (RUL) pneumonia. On
admission, he was found to have a RUL cavitary lung lesion on chest CT (Fig 1). Sputum culture for
tuberculosis and quantiferon gold were negative. Immune work up and ACE level were normal. Serology
for coccidioides, histoplasma, and blastomyces were negative. Serum galactomannan was normal at
0.063. Aspergillus fumigatus IgG was elevated at 168 mg/L. Cultures from broncheoalveolar lavage (BAL)
was unremarkable but showed an elevated galactomannan at 2.73. Histopathology of the resected
mass from the RUL showed aspergilloma and patchy pulmonary necrosis. Fungal culture from the
resected lesion confirmed aspergillus fumigatus.
Discussion: Chronic pulmonary aspergillosis refers to a spectrum of diseases from simple aspergilloma
to progressive cavitary aspergillosis. Chronic cavitary pulmonary aspergillosis (CCPA) describes a
pattern of disease in immunocompetent patients in whom one or more pulmonary cavities are formed.
[1] Aspergilloma, on the other hand, is a fungus ball that can arise in preexisting pulmonary cavities that
have been colonized with Aspergillus [1]. Diagnostic criteria for CCPA include pulmonary symptoms or
progressive radiographic abnormalities over a three month period, elevated Aspergillus IgG antibody
which is seen in over 90% of patients, typically in an immunocompetent host with 1 or more underlying
pulmonary disorders [1, 2]. Since aspergilloma may occur in the context of CCPA, the distinction
between the two relies in symptomatology, evidence of inflammation and radiologic appearance. This
case in unique in that our patient did not have underlying pulmonary disease or immune deficiency.
There is little data that exists regarding the prevalence of these diseases in the pediatric population, as
the majority of reported cases occur in adults. Surgical resection of aspergilloma can prevent or treat life
threatening hemoptysis and is usually curative. In contrast, vast majority of patients with CCPA would
require antifungal therapy with the exception of asymptomatic patients with radiographically and
serologically stable disease. [1,2]
Conclusions: CCPA with aspergilloma formation is rare diagnosis in immunocompetent patients
especially in the absence of an underlying lung disease. The clinical presentation can mimick pulmonary
tuberculosis, therefore, should be considered in patients with chronic cough, hemoptysis and cavitary
lung lesion.
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Fig 1: RUL cavitary lung lesion
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